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ABSTRACT 23 
Raloxifene positively affects mechanical properties of the bone matrix in part through 24 
modification of skeletal bound water. The goal of this study was to determine if raloxifene-25 
induced alterations in skeletal hydration could be measured in vivo using ultra-short echotime 26 
magnetic resonance imaging (UTE-MRI).  Twelve skeletally mature female beagle dogs 27 
(n=6/group) were treated for 6 months with oral doses of saline vehicle (VEH, 1 ml/kg/day) or 28 
raloxifene (RAL, 0.5 mg/kg/day).  Following six months of treatment, all animals underwent in 29 
vivo UTE-MRI of the proximal tibial cortical bone.  UTE-MRI signal intensity versus echotime 30 
curves were analyzed by fitting a double exponential to determine the short and long relaxation 31 
times of water with the bone (dependent estimations of bound and free water, respectively). 32 
Raloxifene-treated animals had significantly higher bound water (+14%; p = 0.05) and lower free 33 
water (-20%) compared to vehicle-treated animals.  These data provide the first evidence that 34 
drug-induced changes in skeletal hydration can be non-invasively assessed using UTE-MRI. 35 
36 
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INTRODUCTION 37 
Raloxifene significantly reduces fracture risk despite minimal effects on bone mineral density (1-38 
3).  Preclinical studies in a dog model have documented a positive effect of raloxifene on 39 
material-level biomechanical properties (the properties of the tissue independent of bone mass) 40 
using both estimated material properties from whole bone tests (vertebra, femoral neck, rib) and 41 
direct assessment on beams from femoral bone (4,5).  Recent work has identified changes in 42 
skeletal hydration, specifically increases in matrix-bound water, as a key factor in this positive 43 
material-level adaption of bone.  Treatment with raloxifene for one year in beagle dogs led to 44 
significantly more total skeletal water, assessed gravimetrically, and this was positively 45 
associated with the bone’s mechanical properties (6).  Ultra-short echotime MRI (UTE-MRI) can 46 
differentiate hydration status of bone under various conditions (7-9).   More detailed assessment 47 
of raloxifene’s effects on bone hydration using UTE-MRI revealed that ex vivo soaking of cortical 48 
bone (both dog and human) in raloxifene resulted in more matrix bound water compared to 49 
control of bone (6).  As UTE-MRI may have potential for clinical application (10), the goal of this 50 
study was to test the hypothesis that UTE-MRI can be used in vivo as a diagnostic indicator to 51 
detect changes in bone hydration caused by pharmacological interventions.   52 
METHODS 53 
Experimental design 54 
Twelve skeletally mature female beagles (1-2 years old) were treated with one of two conditions 55 
for 6 months (n=6 per group): daily oral saline vehicle (1 mL/kg) or daily oral raloxifene (0.5 56 
mg/kg).  Raloxifene was dissolved in 10% hydroxypropyl-β-cyclodextrin and administered at a 57 
dose consistent with the clinical management of post-menopausal osteoporosis on a mg/kg 58 
basis. This dose has been shown previously to alter mechanical properties in this animal model 59 
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following 6 months (11) and one year of treatment (4,5,12).  After six months of treatment, all 60 
animals underwent in vivo UTE-MRI. All procedures were approved by the Indiana University 61 
School of Medicine Animal Care and Use Committee, and were conducted in accordance with 62 
NIH and USDA guidelines on animal care and use prior to the start of the study.   63 
Ultra-short Echotime MRI (UTE-MRI) 64 
Prior to imaging, anesthesia was induced with a combination of ketamine (8mg/kg) and 65 
diazepam (0.3mg/kg) via the cephalic vein. Anesthesia was maintained on 1-2% Isoflurane 66 
(balanced with medial grade oxygen) delivered at 2 L/min via mask. The hind limbs were 67 
immobilized in a custom configured splint that permitted precise placement of the two channel 68 
Miniflex surface coils (Rapid MR International) laterally over the diaphysis inferior to the tibial 69 
plateau.  The splint and surface coils were then secured to a custom configured leg stabilization 70 
platform permitting precise and repeatable iso-center alignment of the hindlimb and coils in the 71 
scanner.  Each animal was scanned on an Siemens 3T Tim Trio MRI using an 3D UTE 72 
sequence with the following characteristics: TR (Time to repeat the sequence) 20 ms; TE1 73 
(Echo time 1) variable (0.05, 0.06, 0.07, 0.08, 0.10, 0.12, 0.14, 0.20, 0.30, 0.40, 0.50, 0.60, 74 
0.80, 1.0, 1.1 ms); TE2 (Echo time 2) 5 ms; Fat Saturation; Average 1, Excitation Flip Angle 50o; 75 
Normalization Filter; Acquisition Matrix 80x80x80; Field of View 50x50; Spatial Resolution 76 
0.63x0.63x0.63 mm, and TA (Total acquisition time) 28 min.  Fat saturation was applied to 77 
prevent signal oscillation with TE (6) and although this may slightly impact the measured bound 78 
water fraction (13), we felt it was a reasonable compromise to avoid potentially greater error due 79 
to signal oscillation. 80 
 81 
Image Analysis 82 
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Image volumes for both variable (TE1) and fixed (TE2) echo times were imported, segmented, 83 
and quantified using Analyze 11.0 (AnalyzeDirect). Marrow and cortical bone for each image 84 
series per animal were segmented on the shortest TE1 image using a region growing technique, 85 
where the distal and proximal limits were prescribed at a fixed distance from the center of the 86 
FOV. Segmented regions were then extracted for all TE1 and TE2 images volumes, thereby 87 
permitting secondary analysis of the UTE signal. To correct for receiver gain offset differences 88 
between successive images, the following scaling was applied: 89 
1,  =

[
2, ]

2, 
 
(1) 
1,  = 1,  ∗ 1,  (2) 
Where, F(TE1, j), M(TE2, j), C(TE1, j), and Cc(TE1, j) are the correction factors at the “jth” TE1, 90 
average marrow intensity at the “jth” TE2, average cortical bone intensity at the “jth” TE1, and 91 
corrected image intensity at the “jth” TE1. To improve model fits in low signal to noise data, 92 
images were corrected according to the methods of Miller and Joseph (14)  and individually 93 
modeled using a double exponential decay (7), with the following modifications: 94 
1,  = 



∗ 
+ 



∗ 
 
(3) 
%  =

 + 
100 (4) 
% = 100 −%  (5) 
 Where, TE1, a, 2#
∗ , b, 2$
∗ , and 1,  are the variable TE as described above, intercept for 95 
the bound fraction, 2∗ for the bound fraction, intercept for the free fraction, 2∗ for the free 96 
fraction, and the noise-free signal decay for the “kth” subject. In order to compute the percent 97 
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bound (%B(k)) and free (%F(k)) water in the system for the “kth” subject, Eqns 4 and 5 were 98 
employed. 99 
Statistics 100 
UTE-MRI data were evaluated using unpaired Students T-tests. Based on our previous work 101 
showed improvement in hydration of raloxifene-treated bone, a one-tailed t-test was used. For 102 
all statistical tests, a priori α-levels were set at 0.05.  103 
RESULTS 104 
Images acquired over the TE1 range from 0.05 to 1.1 ms resulted in high signal to noise ratios 105 
which ranged from 3.89±0.207 to 2.41±0.093, respectively (Figure 1A-B). Standardized 106 
segmentation of UTE images resulted in uniform cortical (170.0±10.5 mm3) and marrow 107 
(62.2±3.79 mm3) volume of interest, and when individually modeled yielded highly consistent 108 
normalized signal as a function of TE1 (Figure 1C). The free and bound T2* time constants for 109 
vehicle and raloxifene were 0.204±0.027, 5.02±1.39, 0.264±0.021, and 7.84±1.59 ms, 110 
respectively. UTE-MRI assessment of bound and free water was assessed in the cortical bone 111 
of the proximal tibia (Figure 2A&B).  Raloxifene treatment for 6 months led to significantly more 112 
bound water (+14%) and significantly less free water (-20%) when compared to vehicle-treated 113 
animals (p=0.05, n=6/grp). 114 
DISCUSSION 115 
Given the emerging interest in UTE-MRI as a tool to assess bone hydration (7-10) and the recent 116 
evidence from our lab that raloxifene positively affects bone hydration (6) we undertook in vivo 117 
measures of free/bound water in animals treated with raloxifene (or vehicle).  Our results 118 
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provide exciting and novel data showing that raloxifene leads to higher bound water compared 119 
to control animals and that this is detectable using in vivo UTE-MRI scanning.   120 
Our analysis showed raloxifene treatment resulted in higher bound water – consistent 121 
with our previous work (6).  In addition, the rate constants from the UTE-MRI were consistent 122 
with previous data in ex vivo bone samples (7).  The mechanisms underlying raloxifene’s positive 123 
effects on bound water remain to be determined.  Our previous work points to the increased 124 
bound water at the collagen/mineral interface, effectively increasing the ability of the mineral 125 
and collagen to dissipate energy and toughen the matrix.  This effect occurs independent of 126 
bone turnover and is cell-independent (6); although there are clearly cell-dependent effects of 127 
raloxifene (15) and these could be contributing to changes in hydration.  128 
The current study using UTE-MRI was only able to assess relative amounts of water 129 
(bound/free).  Thus, it’s possible that changes in bound water were influenced by changes in 130 
free water.  Although we were not able to directly measure porosity, a major determinant of free 131 
water, in these animals we have previously documented the intracortical turnover rate of tibia in 132 
this age dog is 1-2% per year (16,17).  Suppression of intracortical remodeling, as would be 133 
expected with raloxifene, would therefore produce minimal changes in porosity, especially over 134 
6 months (the remodeling cycle in a dog is ~ 3 months long (18)).  Based on this, it is unlikely free 135 
water changes would account for the entire difference between groups quantified in the current 136 
work.  Future work should employ standards that allow absolute volumes of free/bound water 137 
using UTE-MRI and/or should confirm these in vivo findings with ex vivo analyses by NMR. 138 
These novel data show for the first time that drug-induced modulation of bone water can 139 
be detected in vivo using UTE-MRI. Alterations in water, both increases and decreases, have 140 
been shown to be associated with biomechanical properties (6,19).  Having the ability to quality 141 
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changes in hydration non-invasively will allow more detailed assessment to track not only how 142 
raloxifene is altering bone properties, by how other interventions affect bone hydration, both in 143 
preclinical and clinical studies.  144 
 145 
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Figure Legends 151 
Figure 1. Images of tibia cross-section (arrow), surrounded by muscle, from the transverse 152 
UTE-MRI at a TE1 of 0.05 (A) and 1.1 ms (B) illustrating the image quality over the range of 153 
TE1 studied. Panel C provides a chart of average normalized signal for with model fits (solid 154 
lines) for VEH (n=6, solid) RAL (n=6, open). Data presented as means ± standard error of the 155 
mean. 156 
 157 
Figure 2. Raloxifene leads to higher bound water (A) and lower free water (B) in the cortical 158 
bone following 6 months of tre tment.  In vivo assessment of hydration was done using UTE-159 
MRI. n= 6 animals per treatment group.  Data presented as means ± standard error of the 160 
mean.  * p = 0.05 between groups using a one-tailed t-test as described in the statistics section.  161 
  162 
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